Jasper Therapeutics JSPR 深 滬
等待開盤 09-17 09:30:00 美东时间
0.5809
+0.011
+1.89%
華盛通- 最 高0.6093
- 今 開0.5768
- 成交量 50.53万股
- 最 低 0.56
- 昨 收 0.5701
- 總市值 1932.92万
- 52周最高 2.69
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 0.3151
- 委 比 -97.12%
- 總股本 3327.46万
- 歷史最高 188.80
- 量 比 1.84
- 振 幅 8.65%
- 歷史最低 0.3151
- 每 手 1
- 風險率 0.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York. Management will engage in a fireside chat, which will be live-streamed and archived on the company's website. Jasper, a clinical-stage biotech company, is developing innovative therapies for immune-mediated diseases, including KP-104, briquilimab, and KP-701.
09-09 12:00
Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 94.25 percent increase over losses of $(1.74) per share from the same period last year.
08-15 04:27
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2
Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.
08-12 17:21
Jasper Therapeutics Completes The Acquisition Of Kira Pharmaceuticals; Announces $132M Private Placement Of Convertible Preferred Stock; Combined Company Operations Expected To Be Funded Through Second Half Of 2028
Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), today announced that Jasper has completed the acquisition of Kira Pharmaceuticals ("Kira"), a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock t...
07-17 05:18
Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001788028/000121390026066782/ea0294010-8k_jasper.htm
06-10 04:10
Jasper Therapeutics shares are trading lower. The company announced its Board has decided to initiate a comprehensive review of strategic alternatives to maximize shareholder value.
Jasper Therapeutics shares are trading lower. The company announced its Board h...
06-02 03:50
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
TD Cowen Downgrades Jasper Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.
05-16 00:45
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.
05-15 22:05
